English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  53292100    線上人數 :  1106
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 		 
搜尋範圍 進階搜尋
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR
計畫說明

瀏覽
典藏機構
作者
題名
日期
統計圖表
機構即時統計
學術趨勢

消息
2019臺灣學術機構典藏
研討會
機構典藏系統RC7版本已
發佈

著作權
出版社及期刊政策查詢
TAIR著作權會議記錄

相關連結
機構典藏計畫網站
ROAR
OpenDOAR
SHERPA
OAIster
JAIRO
Ira
DSPACE
RWWR
臺大學術典藏NTU Scholars
臺灣機構典藏 TAIR >  依作者瀏覽

"shao y y"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 191-240 / 396 (共8頁)
<< < 1 2 3 4 5 6 7 8 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-05-07T02:46:37Z Young patients with colorectal cancer have increased risk of second primary cancers YI-HSIN LIANG; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S.
臺大學術典藏 2021-05-07T02:46:36Z Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study YI-HSIN LIANG; Shao Y.-Y.; Chen H.-M.; Cheng A.-L.; Lai M.-S.; Yeh K.-H.
臺大學術典藏 2021-05-07T02:46:36Z Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice YI-HSIN LIANG; Shao Y.-Y.; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2021-05-07T02:46:34Z Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer YI-HSIN LIANG; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏 2021-05-03T02:21:08Z Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions Shao Y.-Y.; Hu F.-C.; JIN-TUNG LIANG; Chiu W.-T.; Cheng A.-L.; Yang C.-H.
臺大學術典藏 2021-04-27T08:36:02Z The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia HUNG-YANG KUO; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏 2021-04-27T08:36:01Z Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; HUNG-YANG KUO; Lien M.-Y.; Shao Y.-Y.; Huang T.-C.; Hsu C.-H.
臺大學術典藏 2021-04-27T08:11:51Z The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia HUNG-YANG KUO; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏 2021-04-27T08:11:50Z Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; HUNG-YANG KUO; Lien M.-Y.; Shao Y.-Y.; Huang T.-C.; Hsu C.-H.
臺大學術典藏 2021-04-26T01:47:25Z Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; MING-CHIH HO; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group
臺大學術典藏 2021-03-19T01:54:21Z Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma Shao Y.-Y.; TSUNG-HAO LIU; Lee Y.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-19T01:54:20Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma TSUNG-HAO LIU; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-19T01:54:20Z Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure TSUNG-HAO LIU; Hsu C.-H.; Shao Y.-Y.
臺大學術典藏 2021-03-19T01:54:20Z Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; TSUNG-HAO LIU; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2021-03-19T01:54:19Z Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma Shao Y.-Y.; TSUNG-HAO LIU; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2021-03-19T01:54:19Z Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; TSUNG-HAO LIU; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-19T01:54:17Z It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade TSUNG-HAO LIU; Shao Y.-Y.; Hsu C.-H.
臺大學術典藏 2021-03-18T03:23:39Z The impact of diabetes mellitus on prognosis of early breast cancer in Asia WEI-WU CHEN; Shao Y.-Y.; Shau W.-Y.; Lin Z.-Z.; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2021-03-18T02:02:48Z Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study Hsu C.-H.;Kang Y.K.;Yang T.-S.;Chia-Tung Shun;Shao Y.-Y.;Su W.-C.;Sandoval-Tan J.;Chiou T.-J.;Jin K.;Hsu C.;Cheng A.-L.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L.
臺大學術典藏 2021-03-18T02:02:23Z Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment Lu L.-C.;Lee Y.-H.;Chang C.-J.;Chia-Tung Shun;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; CHIA-TUNG SHUN; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2021-03-15T07:44:49Z Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏 2021-03-15T07:44:49Z Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy Shao Y.-Y.; LI-CHUN LU; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2021-03-15T07:44:49Z Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems Shao Y.-Y.; LI-CHUN LU; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:48Z �]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma LI-CHUN LU; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2021-03-15T07:44:48Z Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma LI-CHUN LU; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2021-03-15T07:44:47Z Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy Shao Y.-Y.; Wu C.-H.; LI-CHUN LU; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:47Z Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy LI-CHUN LU; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:46Z Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials Shao Y.-Y.; Shau W.-Y.; Chan S.-Y.; LI-CHUN LU; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:45Z Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study Li-Chun Lu;Chen P.-J.;Yeh Y.-C.;Hsu C.-H.;Chen H.-M.;Lai M.-S.;Shao Y.-Y.;Cheng A.-L.; LI-CHUN LU; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:45Z Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma Lin H.-H.; Feng W.-C.; LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:44Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma Liu T.-H.;Shao Y.-Y.;Li-Chun Lu;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; Shao Y.-Y.; LI-CHUN LU; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:44Z Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment Li-Chun Lu;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; LI-CHUN LU; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2021-03-15T07:44:43Z Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma Shao Y.-Y.;Liu T.-H.;Hsu C.;Li-Chun Lu;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; Shao Y.-Y.; Liu T.-H.; Hsu C.; LI-CHUN LU; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2021-03-15T07:44:43Z Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Li-Chun Lu;Hsu C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L.; LI-CHUN LU; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:42Z Solving the deficit of cancer pain management skills by education programs Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; LI-CHUN LU; Hsu C.-H.
臺大學術典藏 2021-03-15T06:27:34Z Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; DWANG-YING CHANG; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏 2021-03-10T05:34:17Z Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; Kuo H.-Y.; Lien M.-Y.; Shao Y.-Y.; Ta-Chen Huang; Hsu C.-H.
臺大學術典藏 2021-03-09T06:46:09Z Fatal thrombocytopenia after oxaliplatin-based chemotherapy Shao Y.-Y.; RUEY-LONG HONG
臺大學術典藏 2021-03-09T06:46:08Z Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma Shao Y.-Y.;Ruey-Long Hong; Shao Y.-Y.; RUEY-LONG HONG
臺大學術典藏 2021-03-09T06:46:06Z Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; RUEY-LONG HONG; Hsu C.-H.; Chengb A.-L.
臺大學術典藏 2021-03-09T05:18:37Z Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma Hsu C.-H.; Ying-Chun Shen; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:36Z Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:34Z High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:33Z Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:31Z Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:31Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:29Z A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Ying-Chun Shen; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏 2021-02-23T08:26:15Z A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma Yang S.-H.;Shao Y.-Y.;Lin C.-C.;Sung-Hsin Kuo;Cheng A.-L.;Yeh K.-H.; Yang S.-H.; Shao Y.-Y.; Lin C.-C.; SUNG-HSIN KUO; Cheng A.-L.; Yeh K.-H.
臺大學術典藏 2021-02-19T06:52:27Z Solving the deficit of cancer pain management skills by education programs Shao Y.-Y.;Lin W.-Y.;Lin C.-P.;Lu L.-C.;Chih-Hung Hsu; Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; Lu L.-C.; CHIH-HUNG HSU
臺大學術典藏 2021-02-19T06:52:27Z The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma Hung Y.-P.;Shao Y.-Y.;Hsu C.;Chih-Hung Hsu;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; Shao Y.-Y.; Hsu C.; CHIH-HUNG HSU; Lee J.-M.; Yang M.-H.; Chao Y.

顯示項目 191-240 / 396 (共8頁)
<< < 1 2 3 4 5 6 7 8 > >>
每頁顯示[10|25|50]項目

DSpace Software Copyright © 2002-2004  MIT   &  Hewlett-Packard   /   Enhanced by   NTU Library IR team